Finally, in CRC several TAAs target of autoantibodies have been widely explored in clinical trials as cancer vaccines as CEA, and MAGE (210), together with other pan-explored TAAs in different cancers as MUC1, EGFR, or Survivin (211). Here, MUC1 is linked to colorectal carcinoma.